Review article · 2022 · Open access
Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
Journal of Clinical Medicine, 11(15), 4459 · Published 30 July 2022 · DOI 10.3390/jcm11154459
In brief
“Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis” is a 2022 review article by Faping Wang and 5 co-authors, published in Journal of Clinical Medicine. OpenAlex counts 20 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Clinical Medicine.
- Citations
- 20
- Most cited in
- 2024 (6)
- Field-weighted impact
- 0.52
- References
- 73
- Authors
- 6
Abstract
Background: More and more trials have been conducted. We aimed to assess the efficacy and safety of different JAKinibs in RA. Methods: A systematic search of randomized controlled trials (RCTs) with JAKinib treatment in RA published in the Medline, Embase, and Cochrane databases up to May 2021 was performed. Results: 37 trials involving 15,174 patients were identified. Pooled analysis revealed that JAKinibs were associated with significant therapeutic improvement in RA patients as determined by ACR20 (RR = 2.03, 95% CI: 1.85 to 2.28) and HAQ-DI (MD = −0.31, 95% CI: −0.33 to −0.28) over placebo. Compared to placebo, JAKinib treatment was also associated with more adverse events (RR = 1.10, p < 0.001; RR = 1.29, p < 0.001; RR = 1.59, p = 0.02). Baricitinib and upadacitinib were related to more frequent adverse events (RR = 1.10; 95% CI: 1.01, 1.21; RR = 1.19; 95% CI: 1.11, 1.28) and infection (RR = 1.22; 95% CI: 1.09, 1.37; RR = 1.38; 95% CI: 1.22, 1.56), whereas only baricitinib was associated with more herpes zoster (RR = 3.15; 95% CI: 1.19, 8.33). Conclusions: JAKinibs were superior to placebo for improving signs, symptoms, and health-related quality of life in RA patients at short term, whereas the overall risk of adverse events and infections were greater with baricitinib and upadacitinib, and a higher risk of herpes zoster was only associated with baricitinib. More trials are needed to investigate the long-term safety.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Wang, F., Tang, X., Zhu, M., Mao, H. Z., Wan, H., & Luo, F. (2022). Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis. Journal of Clinical Medicine, 11(15), 4459. https://doi.org/10.3390/jcm11154459
MLA 9
Wang, Faping, et al. “Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis.” Journal of Clinical Medicine, vol. 11, no. 15, 2022, p. 4459. https://doi.org/10.3390/jcm11154459.
Chicago
Wang, Faping, Xiaoju Tang, Min Zhu, Hui Z. Mao, Huajing Wan, and Fengming Luo. 2022. “Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis.” Journal of Clinical Medicine 11 (15): 4459. https://doi.org/10.3390/jcm11154459.
Harvard
Wang, F. et al. (2022) ‘Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis’, Journal of Clinical Medicine, 11(15), p. 4459. doi:10.3390/jcm11154459.
IEEE
F. Wang, X. Tang, M. Zhu, H. Z. Mao, H. Wan, and F. Luo, “Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis,” Journal of Clinical Medicine, vol. 11, no. 15, p. 4459, 2022, doi: 10.3390/jcm11154459.
BibTeX
@article{wang2022efficacy,
title = {{Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis}},
author = {Wang, Faping and Tang, Xiaoju and Zhu, Min and Mao, Hui Z. and Wan, Huajing and Luo, Fengming},
journal = {Journal of Clinical Medicine},
year = {2022},
volume = {11},
number = {15},
pages = {4459},
doi = {10.3390/jcm11154459},
url = {https://doi.org/10.3390/jcm11154459}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 4 | |
| 2024 | 6 | |
| 2025 | 5 | |
| 2026 | 4 |
Its field-weighted citation impact is 0.52: it has been cited 0.52 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- JAK inhibitors
- rheumatoid arthritis
- baricitinib
- upadacitinib
- adverse events
- infection
- herpes zoster
- ACR20 response
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Wang, F., Tang, X., Zhu, M., Mao, H. Z., Wan, H., & Luo, F. (2022). Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis. Journal of Clinical Medicine, 11(15), 4459. https://doi.org/10.3390/jcm11154459
How many times has this paper been cited?
20 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Clinical Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Faping Wang, Xiaoju Tang, Min Zhu, Hui Z. Mao, Huajing Wan, Fengming Luo.
What is the DOI of this paper?
10.3390/jcm11154459, permanently at https://doi.org/10.3390/jcm11154459. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.